Posted by admin on Mar 31, 2019 in |
An essential pathological phenotype of chronic obstructive pulmonary disease is emphysema or lung tissue destruction. The study aims to assess docosahexaenoic acid (DHA), a precursor for specialized pro-resolving mediators, as a treatment of emphysema. Albino mice were challenged with porcine pancreatic elastase on day 1 and bacterial lipopolysaccharide on day 21 to induce emphysema. The pathological condition was then treated with docosahexaenoic acid for 7 consecutive days. The animals were treated with three experimental doses of docosahexaenoic acid (3, 10 and 30 mg/kg b.w.) and results were compared with another 2 groups receiving standard drugs, i.e., corticosteroid and bronchodilators. Histopathology, automated morphometry, bronchoalveolar lavage (BAL) and lung volume measurements were performed. The experiments showed that the 30 mg/kg dose of DHA has treatment effects similar to the standard drugs. The neutrophil is an inflammatory mediator, and the new treatment was able to reduce the neutrophil count in the bronchoalveolar lavage fluid. Lung volumes were reduced suggesting lesser hyperinflation. Histopathology confirms more inferior airway obstruction in the treatment groups. Even...
Read More
Posted by admin on Feb 28, 2019 in |
In this study, we developed a cheap and precise analytic method to measure Etodolac concentration in bulk and pharmaceutical formula. The modified, updated method depends on the reaction between ferric ion and Etodolac to yield ferrous ion. Then the former ion reacted with potassium ferric cyanide to form colored compound has a maximum absorbance at 700 nm. The method was validated by calculating the precision and accuracy. The method follows Beer-Lamber law so that we used the range between 1-22.5 µg/mL and the correlation coefficient at 0.997. Accuracy and precision of the proposed method were estimated and shown average of recoveries between (96.67-99.0%) with precision represented by RSD % equal to 1.02. We also calculated the detection limit (LOD) and quantitative limit (LOQ), which respectively were 0.6 µg/mL and 1.2 µg/mL. The modified suggested method was used to measure Etodolac in pharmaceutical preparation without drug additives interference and shows a good agreement with the standard method. Therefore, it can be used for routine works for quality control for the...
Read More
Posted by admin on Feb 28, 2019 in |
Background: Diabetic nephropathy (DN) is a primary cause of end-stage renal disease globally. Activation of mTOR and reduced autophagy has been identified as one of the pathogenic pathways. The presently available drugs have been successful in inhibiting the mTOR signaling, but show low oral bioavailability and suboptimal solubility. Rapamycin is a selective inhibitor of mTOR, shown significant protection against DN. However, its continuous use is associated with side effects. Thus, the search for novel drugs is on great demand. In the present study, in-silico approaches have been adopted to identify potential compounds with optimal oral bioavailability and better solubility properties, with no toxic effect. Materials and method: The receptor protein mTOR with PDB ID: 3FAP was retrieved from the RCSB protein data bank. Total 20 compounds were selected from the list of 113, obtained from LC-MS of Lalchandan. Further, in-silico molecular docking calculation was done by using YASARA software. Drug-likeness and molecular property of best-docked compounds were checked by using Lipinski rule of five and Admet SAR server. Result:...
Read More
Posted by admin on Feb 28, 2019 in |
Abelmoschus esculentus Linn. (Malvaceae) is described in medicine for the treatment of diabetes mellitus. The monech seeds of Abelmoschus esculentus having potential in the development of a drug for diabetes due to their antidiabetic activity. The hypoglycemic effect of the extract was tested in normal, glucose loading and alloxan-induced diabetic rats. Aqueous and ethanolic extracts (250 and 500 mg/kg body weight), were administered orally to male Wistar albino rats. The parameters studied included oral glucose tolerance test in blood, fasting blood glucose, serum insulin, and glycated hemoglobin levels, liver glycogen content, serum lipid profile, and changes in body weights. The extracts produced a dose-dependent fall in fasting blood glucose (FBG). After 15 days of treatment with extracts, the maximum reduction in FBG (35.14%) was observed in diabetic rats treated with ethanolic extract 500 mg/kg dose. Serum lipid levels were reversed towards near normal, and control in the loss of body weight was observed in treated rats as compared to diabetic control. The extract treatment also showed a significant increase...
Read More
Posted by admin on Feb 28, 2019 in |
The liquisolid technique was chosen to enhance the dissolution properties of Candesartan. The study aimed to investigate the complexation of Candesartan with β-cyclodextrin in improving the dissolution profile of Candesartan. Candesartan is a BCS class-II drug. The inclusion complexes were formed by physical mixing (1:1 ratio). Liquisolid compacts were prepared by using, propylene glycol, tween 20 as the nonvolatile liquid vehicles. Avicel pH 102 was used as the carrier and aerosil 200 as a coating material and sodium starch glycolate as the disintegrant respectively. The pre-formulation studies like melting point, flow properties of Candesartan were compiled with IP standards. The FT-IR spectra revealed that there was no interaction between drug and excipient. Liquisolid compact (LS8) was showing the best release. Stability studies showed that there were no significant changes in physical and chemical properties of a tablet of formulation LS8 after 3 months. This research work has produced encouraging results in terms of increasing the in-vitro dissolution of poorly soluble drugs such as Candesartan using liquisolid technology. The technique...
Read More
